Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The Company focuses on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes for treatment of patients with cancer. Iovance Biotherapeutics serves customers in the United States.
Website: iovance.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.06 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -19.6% (LTM)

Entry Point: Share price is 141.0% higher than minimum and 77.1% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: IOVA
Share price, USD:  (+1.0%)4
year average price 2.62  


year start price 2.24 2025-06-13

min close price 1.69 2025-06-27

max close price 4.38 2026-06-04

current price 4.00 2026-06-12
Common stocks: 157 168 000

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 629
Net Debt ($m): -30
EV (Enterprise Value): 599
Price to Book: 0.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-05globenewswire.com

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

2026-01-16globenewswire.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

2025-12-29seekingalpha.com

Iovance Biotherapeutics: Bright Prospects For 2026

2025-12-19globenewswire.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

2025-11-21globenewswire.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

2025-11-11seekingalpha.com

Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode

2025-11-07zacks.com

IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y

2025-11-06seekingalpha.com

Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript

2025-11-06zacks.com

Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates

2025-10-29globenewswire.com

IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-07 2024-11-07 2024-08-08 2024-05-09 2023-11-07 2023-08-08 2023-05-10 2022-11-03
acceptedDate 2025-11-06 09:15:49 2025-08-07 17:16:03 2025-02-27 17:15:54 2024-11-07 17:15:37 2024-08-08 17:10:32 2024-05-09 17:10:44 2024-02-28 17:15:45 2023-11-07 17:15:48 2023-08-08 17:15:40 2023-05-10 16:30:58 2023-02-28 17:15:47 2022-11-03 17:16:37 2022-02-24 17:14:55 2021-02-25 17:15:37
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 67M 60M 164M 59M 31M 715 000 1M 469 000 238 000 0 0 0 0 0
costOfRevenue 1M 57M 124M 40M 37M 13M 11M 4M 2M 0 0 0 0 0
grossProfit 66M 3M 40M 19M -6M -12M -10M -4M -2M 0 0 0 0 0
grossProfitRatio 0.979 0.055 0.32 -0.181 -16.531 -8.254 -7.613 0 0
researchAndDevelopmentExpenses 75M 79M 282M 68M 62M 80M 344M 88M 86M 83M 295M 73M 259M 202M
generalAndAdministrativeExpenses 0 0 0 0 0 8M 0 27M 22M 28M 104M 28M 84M 60M
sellingAndMarketingExpenses 0 0 0 0 0 18M 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 35M 38M 153M 40M 34M 26M 107M 27M 22M 28M 104M 28M 84M 60M
otherExpenses 51M 0 0 -1000 0 0 0 0 0 0 0 0 0 0
operatingExpenses 161M 117M 435M 108M 96M 106M 451M 114M 108M 111M 399M 100M 343M 262M
costAndExpenses 162M 174M 559M 148M 133M 118M 462M 119M 110M 111M 399M 100M 343M 262M
interestIncome 0 4M 20M 4M 3M 3M 13M 3M 3M 3M 3M 777 000 451 000 2M
interestExpense 0 0 0 0 0 0 0 0 0 -3M 3M 777 000 0 0
depreciationAndAmortization 9M 12M 44M 0 11M 10M 33M 10M 8M 6M 21M 0 14M 1M
ebitda -85M -102M -352M -89M -91M -108M -427M -118M -110M -111M -378M -100M -329M -261M
ebitdaratio -1.255 -1.699 -1.521 -2.927 -150.79 -252.369 -462.546 0 0
operatingIncome -95M -114M -395M -89M -102M -118M -461M -118M -110M -111M -399M -100M -343M -262M
operatingIncomeRatio -1.407 -1.898 -1.521 -3.276 -164.646 -252.369 -462.546 0 0
totalOtherIncomeExpensesNet 1M 4M 20M 4M 3M 3M 13M 3M 3M 3M 3M 777 000 451 000 2M
incomeBeforeTax -94M -110M -375M -85M -99M -114M -448M -115M -107M -107M -396M -100M -342M -260M
incomeBeforeTaxRatio -1.388 -1.829 -1.453 -3.168 -159.978 -245.209 -449.601 0 0
incomeTaxExpense -2M 2M -3M -2M -1M -1M -3M -1M -477 000 -3M 0 -777 000 0 0
netIncome -91M -112M -372M -84M -97M -113M -444M -114M -107M -104M -396M -99M -342M -260M
netIncomeRatio -1.353 -1.862 -1.427 -3.122 -158.008 -242.559 -447.597 0 0
eps -0.25 -0.33 -1.28 -0.28 -0.34 -0.42 -1.89 -0.46 -0.47 -0.49 -2.49 -0.63 -2.23 -1.88
epsdiluted -0.25 -0.33 -0.28 -0.34 -0.42 -0.46 -0.47 -0.49 -0.63
weightedAverageShsOut 364M 335M 290M 303M 285M 266M 235M 246M 224M 214M 159M 158M 153M 138M
weightedAverageShsOutDil 364M 335M 290M 303M 285M 266M 235M 246M 224M 214M 159M 158M 153M 138M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-28 2023-02-28 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 20M 13M 0 451 000 2M
ebit -395M -461M -399M -343M -262M
nonOperatingIncomeExcludingInterest 0 0 0 0 0
netIncomeFromContinuingOperations -372M -444M -396M -342M -260M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -372M -444M -396M -342M -260M
epsDiluted -1.28 -1.89 -2.49 -2.23 -1.88

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-07 2024-11-07 2024-08-08 2024-05-09 2023-11-07 2023-08-08 2023-05-10 2022-11-03
acceptedDate 2025-11-06 09:15:49 2025-08-07 17:16:03 2025-02-27 17:15:54 2024-11-07 17:15:37 2024-08-08 17:10:32 2024-05-09 17:10:44 2024-02-28 17:15:45 2023-11-07 17:15:48 2023-08-08 17:15:40 2023-05-10 16:30:58 2023-02-28 17:15:47 2022-11-03 17:16:37 2022-02-24 17:14:55 2021-02-25 17:15:37
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 158M 132M 116M 164M 229M 134M 115M 268M 230M 543M 232M 118M 78M 67M
shortTermInvestments 143M 169M 208M 233M 184M 222M 165M 94M 21M 83M 240M 242M 426M 562M
cashAndShortTermInvestments 301M 301M 324M 397M 413M 356M 280M 361M 251M 626M 472M 360M 504M 629M
netReceivables 67M 60M 69M 56M 32M 234 000 151 000 1 33 000 0 0 0 0 0
inventory 52M 50M 52M 39M 28M 18M 10M 9M 10M 0 0 0 0 0
otherCurrentAssets 10M 12M 12M 7M 10M 11M 17M 12M 14M 11M 7M 10M 0 0
totalCurrentAssets 429M 423M 457M 499M 482M 386M 308M 383M 275M 638M 479M 370M 508M 636M
propertyPlantEquipmentNet 175M 172M 164M 179M 180M 183M 177M 179M 180M 180M 178M 169M 170M 114M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 285M 296M 282M 307M 295M 294M 229M 224M 236M 0 0 0 0 0
goodwillAndIntangibleAssets 285M 296M 282M 307M 295M 294M 229M 224M 236M 0 0 0 0 0
longTermInvestments 6M 0 0 0 6M 6M 66M 66M 66M 0 0 0 92M 0
taxAssets 0 0 0 0 0 0 0 -66M -66M 0 0 0 0 0
otherNonCurrentAssets 9M 16M 7M 7M 327 000 259 000 270 000 67M 67M 7M 7M 7M 8M 18M
totalNonCurrentAssets 476M 485M 453M 493M 482M 484M 473M 470M 482M 187M 185M 176M 269M 132M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 905M 907M 910M 991M 964M 870M 780M 852M 757M 825M 664M 546M 777M 768M
accountPayables 31M 32M 28M 32M 20M 26M 33M 19M 31M 32M 27M 24M 27M 14M
shortTermDebt 7M 8M 0 0 23M 11M 0 10M 11M 13M 0 7M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 87M 89M 50M 86M 50M 46M 35M 61M 47M 43M 0 48M 0 0
totalCurrentLiabilities 126M 129M 122M 118M 94M 83M 110M 91M 89M 87M 91M 79M 89M 55M
longTermDebt 45M 45M 1 000 000 67M 70M 1 000 000 1 000 000 68M 70M 70M 1 000 000 73M 1 000 000 0
deferredRevenueNonCurrent 0 0 0 0 68M 71M 0 0 -1 000 000 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 32M 35M 32M 32M 32M 33M 17M 18M 20M 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 1 000 000 0 1 000 000 1 000 000 1 000 000 0 42M 0 12M
totalNonCurrentLiabilities 77M 80M 78M 100M 102M 107M 85M 87M 90M 71M 73M 73M 66M 57M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 45M 52M 57M 66M 81M 72M 75M 78M 80M 82M 84M 79M 71M 52M
totalLiabilities 203M 209M 200M 218M 196M 190M 196M 178M 179M 158M 164M 152M 156M 112M
preferredStock 2000 2000 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000 4000
commonStock 16 000 14 000 13 000 13 000 12 000 12 000 11 000 11 000 9000 9000 8000 7000 7000 6000
retainedEarnings -2 704M -2 612M -2 385M -2 306M -2 222M -2 125M -2 012M -1 896M -1 782M -1 676M -1 568M -1 463M -1 172M -830M
accumulatedOtherComprehensiveIncomeLoss 16M 21M -1M 16M 526 000 116 000 3M -9M 325 000 -126 000 -902 000 -2M -601 000 19 000
othertotalStockholdersEquity 3 390M 3 290M 3 063M 2 990M 2 805M 2 579M 2 360M 2 343M 1 859M
totalStockholdersEquity 702M 698M 710M 773M 769M 680M 585M 674M 579M 667M 500M 394M 622M 656M
totalEquity 702M 698M 710M 773M 769M 680M 585M 674M 579M 667M 500M 394M 622M 656M
totalLiabilitiesAndStockholdersEquity 905M 907M 991M 964M 870M 852M 757M 825M 546M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 905M 907M 910M 991M 964M 870M 780M 852M 757M 825M 664M 546M 777M 768M
totalInvestments 149M 169M 208M 233M 190M 228M 231M 94M 21M 83M 240M 242M 518M 562M
totalDebt 52M 53M 58M 79M 82M 84M 76M 78M 81M 82M 85M 80M 72M 52M
netDebt -106M -79M -57M -85M -147M -50M -39M -189M -149M -461M -146M -38M -7M -16M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-28 2023-02-28 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 69M 151 000 0 0 0
otherReceivables 0 0 0 0 0
prepaids 0 0 0 4M 7M
totalPayables 28M 33M 27M 27M 14M
otherPayables 0 0 0 0 0
accruedExpenses 32M 35M 52M 57M 35M
capitalLeaseObligationsCurrent 13M 8M 13M 5M 6M
capitalLeaseObligationsNonCurrent 44M 67M 72M 65M 45M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 3 096M 2 594M 2 069M 1 795M 1 487M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-07 2024-11-07 2024-08-08 2024-05-09 2023-11-07 2023-08-08 2023-05-10 2022-11-03
acceptedDate 2025-11-06 09:15:49 2025-08-07 17:16:03 2025-02-27 17:15:54 2024-11-07 17:15:37 2024-08-08 17:10:32 2024-05-09 17:10:44 2024-02-28 17:15:45 2023-11-07 17:15:48 2023-08-08 17:15:40 2023-05-10 16:30:58 2023-02-28 17:15:47 2022-11-03 17:16:37 2022-02-24 17:14:55 2021-02-25 17:15:37
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -91M -112M -372M -84M -97M -113M -444M -114M -107M -107M -396M -100M -342M -260M
depreciationAndAmortization 12M 12M 44M 2M 11M 10M 33M 10M 8M 6M 21M 5M 14M 1M
deferredIncomeTax -2M 2M -3M -2M -1M -1M -3M -1M -477 000 0 0 0 0 2M
stockBasedCompensation 0 15M 110M 31M 30M 17M 63M 16M 17M 16M 84M 20M 70M 41M
changeInWorkingCapital -9M 9M -123M 71M -39M -33M -7M 6M -11M -13M -3M 11M 25M 3M
accountsReceivables -7M 11M -69M -24M -31M -83 000 -149 000 33 000 -33 000 0 0 0 0 0
inventory -3M 7M -40M -11M -9M -7M -10M 354 000 -10M 0 0 0 0 0
accountsPayables -4M 893 000 -8M 14M -10M -6M 5M -10M 146 000 3M 6M 4M 7M -3M
otherWorkingCapital 6M -10M -6M 92M 12M -20M -1M 15M -2M -3M -9M 7M 18M 6M
otherNonCashItems 12M 6M -9M -78M 100M 47M -4M -666 000 -58 000 -978 000 871 000 133 000 6M 8M
netCashProvidedByOperatingActivities -79M -67M -353M -59M -98M -122M -362M -84M -94M -100M -293M -64M -228M -205M
investmentsInPropertyPlantAndEquipment -11M -7M -11M -2M -442 000 -4M -22M -4M -10M -6M -20M -1M -38M -47M
acquisitionsNet 0 0 -53M 0 0 -53M -213M -3M -210M 0 -277M 0 -38M 271M
purchasesOfInvestments -92M -69M -461M -157M -74M -142M -206M -93M 210M -5M -246M -64M -725M -948M
salesMaturitiesOfInvestments 120M 90M 428M 110M 115M 87M 286M 21M 62M 164M 523M 139M 763M 677M
otherInvestingActivites 0 0 0 41M -55M -72M -210M 0 0
netCashUsedForInvestingActivites 17M 14M -49M 40M -112M -79M -157M 153M 74M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 89M 13M 48M 152M 198M 203M 1M 260M 0
commonStockRepurchased 0 0 0 0 0 -5M 0 -379 000 -301 000 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -466 000 165 000 -6M 952 000 -5M -379 000 0 -2M 225 000
netCashUsedProvidedByFinancingActivities 88M 13M 42M 153M 194M 203M 1M 258M 225 000
effectOfForexChangesOnCash -701 000 739 000 -541 000 1M -125 000 -491 000 -3M -2M -4M 0 0 0 0 0
netChangeInCash 26M -40M -59M -65M 95M 19M -57M 38M -253M 312M 154M 10M 11M 53M
cashAtEndOfPeriod 158M 138M 122M 171M 229M 134M 181M 268M 296M 550M 238M 125M 84M 73M
cashAtBeginningOfPeriod 132M 178M 181M 229M 134M 115M 238M 230M 550M 238M 84M 115M 73M 19M
operatingCashFlow -79M -67M -353M -59M -98M -122M -362M -84M -94M -100M -293M -64M -228M -205M
capitalExpenditure -11M -7M -11M -2M -442 000 -4M -22M -4M -10M -6M -20M -1M -38M -47M
freeCashFlow -90M -75M -364M -61M -99M -126M -384M -88M -103M -105M -313M -65M -266M -252M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-28 2023-02-28 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 277M 38M -271M
netCashProvidedByInvestingActivities -96M -155M 256M 132 000 -318M
netDebtIssuance 0 0 0 1 000 000 0
longTermNetDebtIssuance 0 0 0 1 000 000 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 397M 463M 190M 203M 567M
netCommonStockIssuance 397M 463M 190M 203M 567M
commonStockIssuance 397M 463M 190M 203M 567M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -7M -322 000 648 000 35M 9M
netCashProvidedByFinancingActivities 391M 463M 190M 239M 576M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-08-08 ET (fiscal 2025 q2)
2025 q1
2025-05-08 ET (fiscal 2025 q1)
2024 q4
2025-02-27 ET (fiscal 2024 q4)
2024 q3
2024-11-07 ET (fiscal 2024 q3)
2024 q2
2024-08-08 ET (fiscal 2024 q2)
2024 q1
2024-05-09 ET (fiscal 2024 q1)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-03-01 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-07 11:05 ET
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
2026-04-27 12:01 ET
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
2026-02-26 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2026-02-24 ET
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
2026-02-24 ET
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
2026-02-11 21:05 ET
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
2026-02-05 22:15 ET
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
2025-11-06 13:00 ET
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
2025-11-03 ET
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
2025-10-23 ET
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
2025-10-15 ET
Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
2025-08-29 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2025-08-18 ET
Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma
2025-07-24 ET
Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025
2025-07-15 ET
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
2025-07-14 ET
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
2025-07-10 ET
Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy
2025-07-08 ET
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Iovance Biotherapeutics Inc. to Contact Law Firm
2025-06-10 ET
Iovance Biotherapeutics to Present at Upcoming Conference
2025-06-02 ET
The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma
2025-05-22 ET
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
2025-05-16 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2025-05-08 ET
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025
2025-05-02 ET
Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025
2025-04-23 ET
Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses
2025-04-18 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2025-03-21 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2025-02-27 ET
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024
2025-02-21 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2025-02-18 ET
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025
2025-02-12 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2025-02-10 ET
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
2025-01-17 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-12-20 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-11-26 ET
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
2024-11-07 ET
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
2024-10-31 20:01 ET
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
2024-09-03 21:00 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2024-08-08 20:01 ET
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
2024-07-29 20:01 ET
Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024
2024-06-28 11:00 ET
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
2024-06-21 21:00 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-05-24 20:01 ET
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
2024-05-23 21:00 ET
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
2024-05-17 21:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-05-09 20:01 ET
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
2024-05-01 10:01 ET
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
2024-04-30 10:01 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2024-04-24 20:01 ET
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
2024-04-19 21:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-03-22 21:30 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-03-04 11:30 ET
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
2024-03-01 22:00 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2024-02-28 21:01 ET
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates 
2024-02-22 13:45 ET
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
2024-02-20 13:00 ET
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma
2024-02-20 11:30 ET
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
2024-02-20 11:30 ET
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
2024-02-16 22:30 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-02-16 20:38 ET
Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024
2024-02-16 20:19 ET
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
2024-01-19 22:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-12-27 12:00 ET
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
2023-12-22 22:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-11-17 22:00 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-11-07 21:01 ET
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
2023-10-31 20:01 ET
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023
2023-10-31 13:05 ET
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
2023-10-20 21:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-10-16 12:15 ET
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress
2023-09-27 20:01 ET
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
2023-09-22 22:25 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-09-14 22:10 ET
U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma
2023-09-07 11:31 ET
Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference
2023-08-18 21:00 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-08-08 20:01 ET
Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates
2023-07-25 20:01 ET
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer
2023-07-24 20:01 ET
Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023
2023-07-21 21:34 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-07-13 20:01 ET
Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering
2023-07-13 ET
Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering
2023-07-11 01:46 ET
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
2023-07-10 20:34 ET
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
2023-07-10 11:00 ET
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer
2023-07-10 ET
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
2023-06-20 11:01 ET
Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape
2023-06-15 11:01 ET
Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma
2023-06-09 11:01 ET
Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference
2023-05-26 21:30 ET
Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma
2023-05-09 20:01 ET
Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
2023-05-02 20:01 ET
Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023
2023-04-24 11:01 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2023-03-24 20:01 ET
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
2023-03-01 13:03 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2023-02-28 21:01 ET
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
2023-02-21 21:01 ET
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
2023-01-23 13:00 ET
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
2022-11-30 12:00 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2022-11-18 11:30 ET
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
2022-11-10 17:33 ET
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2022-11-07 13:01 ET
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2022-11-03 20:01 ET
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates
2022-10-24 20:01 ET
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022
2022-10-10 11:30 ET
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy
2022-10-05 12:05 ET
Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
2022-09-06 20:01 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2022-09-06 13:00 ET
Iovance Biotherapeutics to Present Posters at ESMO 2022
2022-08-25 11:30 ET
Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
2022-08-04 20:01 ET
Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates
2022-07-27 11:00 ET
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022
2022-07-22 21:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2022-06-17 21:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2022-06-13 20:01 ET
Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors
2022-06-08 20:01 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2022-05-26 20:01 ET
Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma
2022-05-20 21:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2022-05-05 20:01 ET
Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate Updates
2022-04-27 20:01 ET
Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting
2022-04-26 11:30 ET
Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 5, 2022
2022-04-25 20:01 ET
Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
2022-04-22 21:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2022-04-05 20:05 ET
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma
2022-03-16 11:01 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2022-03-15 21:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2022-03-08 21:31 ET
Iovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
2022-02-24 21:01 ET
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates
2022-02-18 22:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2022-02-11 21:01 ET
Iovance Biotherapeutics to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast on Thursday, February 24, 2022
2022-01-21 22:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2022-01-10 13:00 ET
Iovance Biotherapeutics Announces Raj K. Puri, M.D., Ph.D. to Join Leadership Team
2022-01-07 21:01 ET
Iovance Biotherapeutics to Present Data on Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
2022-01-06 22:38 ET
Iovance Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022
2021-12-17 22:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2021-12-07 13:40 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2021-11-19 22:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2021-11-13 21:30 ET
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2021-11-12 12:01 ET
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2021-11-09 13:54 ET
Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2021-11-08 21:01 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2021-11-04 20:01 ET
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2021 Financial Results and Corporate Updates
2021-10-25 20:01 ET
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 4, 2021
2021-10-18 20:01 ET
Iovance Biotherapeutics to Host Conference Call and Webcast to Highlight Data at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2021-10-01 12:47 ET
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapies Across Multiple Solid Tumors and Treatment Settings at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
2021-09-28 21:00 ET
Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC) in the Philadelphia Navy Yard
2021-09-23 11:30 ET
Iovance Biotherapeutics Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy Manufactured at Iovance Cell Therapy Center (iCTC)
2021-08-05 20:01 ET
Iovance Biotherapeutics Reports Second Quarter and First Half 2021 Financial Results and Corporate Updates
2021-07-19 20:30 ET
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 5, 2021
2021-06-29 19:38 ET
Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET
2021-06-29 10:30 ET
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer
2021-06-06 13:24 ET
Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting
2021-06-04 13:08 ET
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting
2021-06-01 11:30 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2021-05-19 21:04 ET
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma at Upcoming ASCO 2021 Annual Meeting
2021-05-18 20:30 ET
Iovance Biotherapeutics Provides Regulatory Update for Lifileucel Potency Assays
2021-05-12 20:35 ET
Journal of Clinical Oncology Publishes Clinical Data for Cohort 2 in Iovance C-144-01 Study of Lifileucel TIL Therapy in Metastatic Melanoma
2021-05-06 20:01 ET
Iovance Biotherapeutics Reports First Quarter 2021 Financial Results and Corporate Updates
2021-05-04 20:30 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2021-04-28 14:50 ET
Iovance Biotherapeutics to Present Clinical Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting
2021-04-27 20:01 ET
Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 6, 2021
2021-04-09 11:00 ET
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma During American Association for Cancer Research (AACR) 2021 Annual Meeting
2021-03-15 20:01 ET
Iovance Biotherapeutics Appoints Igor Bilinsky as Chief Operating Officer
2021-03-10 22:28 ET
Iovance Biotherapeutics to Present Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at American Association for Cancer Research (AACR) 2021 Annual Meeting
2021-03-01 21:01 ET
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
2021-02-25 21:01 ET
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates
2021-02-18 12:30 ET
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25, 2021
2021-01-19 13:56 ET
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
2020-12-28 12:30 ET
Iovance Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021
2020-12-14 12:00 ET
Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer
2020-11-30 12:21 ET
Iovance Biotherapeutics to Present at Upcoming Conferences in December
2020-11-09 13:00 ET
Iovance Biotherapeutics Presents Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
2020-11-05 21:00 ET
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2020 Financial Results and Corporate Updates
2020-10-30 11:00 ET
Iovance Biotherapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5, 2020
2020-10-28 11:45 ET
Iovance Biotherapeutics to Present at Upcoming Conferences in November
2020-10-14 21:01 ET
Iovance Biotherapeutics to Present Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
2020-10-06 11:00 ET
Iovance Biotherapeutics to Present at Upcoming October Conferences
2020-10-05 20:01 ET
Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma
2020-08-07 11:30 ET
Iovance Biotherapeutics to Present at BTIG Biotechnology Conference 2020
2020-08-06 20:01 ET
Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update
2020-08-06 12:05 ET
Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001
2020-07-23 11:30 ET
Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020
2020-06-08 20:01 ET
Iovance Biotherapeutics to Present at Upcoming June Conferences
2020-06-02 20:01 ET
Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public Offering
2020-05-29 12:01 ET
Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program
2020-05-29 01:30 ET
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock
2020-05-27 20:20 ET
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
2020-05-27 20:01 ET
Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma
2020-05-13 21:01 ET
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma
2020-05-05 20:01 ET
Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update
2020-04-29 16:01 ET
Iovance Biotherapeutics to Present Updated Data from Clinical Study in Advanced Melanoma at ASCO 2020 Virtual Scientific Program
2020-04-27 20:01 ET
Iovance Biotherapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, May 5, 2020
2020-04-13 21:14 ET
Iovance Biotherapeutics Announces H. Lee Moffitt Cancer Center to Present Lung Cancer Clinical Data at American Association for Cancer Research (AACR) Virtual Annual Meeting 2020
2020-03-02 21:01 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2020-02-25 21:01 ET
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
2020-02-19 12:00 ET
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Tuesday, February 25, 2020
2020-02-12 12:00 ET
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
2020-01-15 13:00 ET
Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel
2020-01-12 21:30 ET
Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog
2020-01-12 21:00 ET
Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement
2019-12-02 12:00 ET
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in December
2019-11-21 12:00 ET
Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy
2019-11-08 12:00 ET
Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer 34th Annual Meeting
2019-11-07 21:32 ET
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in November
2019-11-04 21:01 ET
Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results
2019-10-31 20:43 ET
Iovance Biotherapeutics to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Monday, November 4, 2019
2019-10-02 11:00 ET
Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting
2019-09-27 20:30 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2019-05-17 13:31 ET
Thinking about buying stock in Aurora Cannabis, Applied Materials, Iovance Biotherapeutics, NVIDIA, or Under Armour?

SEC forms

Show financial reports only

SEC form 8
2026-05-07 13:18 ET
Iovance Biotherapeutics published news for 2026 q1
SEC form 8
2026-05-07 13:18 ET
Iovance Biotherapeutics published news for 2026 q1
SEC form 10
2026-05-07 13:16 ET
Iovance Biotherapeutics published news for 2026 q1
SEC form 10
2026-02-24 09:35 ET
Iovance Biotherapeutics reported for 2025 q4
SEC form 8
2026-02-24 08:00 ET
Iovance Biotherapeutics published news for 2025 q4
SEC form 8
2026-02-24 08:00 ET
Iovance Biotherapeutics reported for 2025 q4
SEC form 8
2026-02-24 08:00 ET
Iovance Biotherapeutics published news for 2025 q4
SEC form 8
2026-01-09 07:35 ET
Iovance Biotherapeutics published news for 2025 q4
SEC form 8
2026-01-09 07:35 ET
Iovance Biotherapeutics published news for 2025 q4
SEC form 10
2025-11-06 09:15 ET
Iovance Biotherapeutics reported for 2025 q3
SEC form 8
2025-11-06 08:05 ET
Iovance Biotherapeutics published news for 2025 q3
SEC form 8
2025-11-06 08:05 ET
Iovance Biotherapeutics reported for 2025 q3
SEC form 8
2025-08-29 16:06 ET
Iovance Biotherapeutics published news for 2025 q2
SEC form 8
2025-08-29 16:06 ET
Iovance Biotherapeutics published news for 2025 q2
SEC form 8
2025-08-22 17:18 ET
Iovance Biotherapeutics published news for 2025 q2
SEC form 8
2025-08-22 17:18 ET
Iovance Biotherapeutics published news for 2025 q2
SEC form 8
2025-08-22 17:18 ET
Iovance Biotherapeutics published news for 2025 q2
SEC form 8
2025-08-19 20:47 ET
Iovance Biotherapeutics published news for 2025 q2
SEC form 8
2025-08-19 20:47 ET
Iovance Biotherapeutics published news for 2025 q2
SEC form 10
2025-08-07 21:16 ET
Iovance Biotherapeutics reported for 2025 q2
SEC form 8
2025-08-07 20:06 ET
Iovance Biotherapeutics published news for 2025 q2
SEC form 8
2025-08-07 20:06 ET
Iovance Biotherapeutics published news for 2025 q2
SEC form 10
2025-05-08 21:15 ET
Iovance Biotherapeutics reported for 2025 q1
SEC form 8
2025-05-08 20:05 ET
Iovance Biotherapeutics published news for 2025 q1
SEC form 8
2025-05-08 20:05 ET
Iovance Biotherapeutics published news for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Iovance Biotherapeutics reported for 2025 q1
SEC form 10
2025-02-27 17:15 ET
Iovance Biotherapeutics reported for 2024 q4
SEC form 8
2025-02-27 16:05 ET
Iovance Biotherapeutics published news for 2024 q4
SEC form 8
2025-02-27 16:05 ET
Iovance Biotherapeutics reported for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Iovance Biotherapeutics reported for 2024 q4
SEC form 8
2025-02-10 12:22 ET
Iovance Biotherapeutics published news for 2024 q4
SEC form 8
2025-02-10 12:22 ET
Iovance Biotherapeutics published news for 2024 q4
SEC form 10
2024-11-07 17:15 ET
Iovance Biotherapeutics reported for 2024 q3
SEC form 8
2024-11-07 16:06 ET
Iovance Biotherapeutics published news for 2024 q3
SEC form 8
2024-11-07 16:06 ET
Iovance Biotherapeutics reported for 2024 q3
SEC form 10
2024-08-08 17:10 ET
Iovance Biotherapeutics reported for 2024 q2
SEC form 8
2024-08-08 16:05 ET
Iovance Biotherapeutics published news for 2024 q2
SEC form 8
2024-08-08 16:05 ET
Iovance Biotherapeutics published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Iovance Biotherapeutics reported for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Iovance Biotherapeutics reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Iovance Biotherapeutics published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Iovance Biotherapeutics published news for 2024 q1
SEC form 10
2024-02-28 17:15 ET
Iovance Biotherapeutics reported for 2023 q4
SEC form 8
2024-02-28 16:05 ET
Iovance Biotherapeutics published news for 2023 q4
SEC form 8
2024-02-28 16:05 ET
Iovance Biotherapeutics reported for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Iovance Biotherapeutics reported for 2023 q4
SEC form 8
2024-02-20 00:00 ET
Iovance Biotherapeutics published news for 2023 q4
SEC form 8
2024-02-20 00:00 ET
Iovance Biotherapeutics published news for 2023 q4
SEC form 8
2024-02-20 00:00 ET
Iovance Biotherapeutics published news for 2023 q4
SEC form 10
2023-11-07 17:15 ET
Iovance Biotherapeutics reported for 2023 q3
SEC form 8
2023-11-07 16:05 ET
Iovance Biotherapeutics published news for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Iovance Biotherapeutics reported for 2023 q3
SEC form 10
2023-08-08 17:15 ET
Iovance Biotherapeutics reported for 2023 q2
SEC form 6
2023-08-08 16:05 ET
Iovance Biotherapeutics reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Iovance Biotherapeutics reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Iovance Biotherapeutics reported for 2023 q2
SEC form 6
2023-07-13 16:31 ET
Iovance Biotherapeutics published news for 2023 q2
SEC form 6
2023-07-11 16:55 ET
Iovance Biotherapeutics published news for 2023 q2
SEC form 6
2023-07-10 16:40 ET
Iovance Biotherapeutics published news for 2023 q2
SEC form 6
2023-07-10 08:53 ET
Iovance Biotherapeutics published news for 2023 q2
SEC form 8
2023-07-10 00:00 ET
Iovance Biotherapeutics published news for 2023 q2
SEC form 6
2023-06-16 16:51 ET
Iovance Biotherapeutics published news for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Iovance Biotherapeutics reported for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Iovance Biotherapeutics published news for 2023 q1
SEC form 6
2023-03-27 07:00 ET
Iovance Biotherapeutics published news for 2022 q4
SEC form 6
2023-03-10 16:44 ET
Iovance Biotherapeutics published news for 2022 q4
SEC form 10
2023-02-28 17:15 ET
Iovance Biotherapeutics reported for 2022 q4
SEC form 6
2023-02-28 16:05 ET
Iovance Biotherapeutics published news for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Iovance Biotherapeutics reported for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Iovance Biotherapeutics published news for 2022 q4
SEC form 6
2023-01-27 17:10 ET
Iovance Biotherapeutics published news for 2022 q4
SEC form 6
2023-01-23 08:14 ET
Iovance Biotherapeutics published news for 2022 q4
SEC form 6
2023-01-10 21:30 ET
Iovance Biotherapeutics published news for 2022 q4
SEC form 6
2022-11-18 17:19 ET
Iovance Biotherapeutics published news for 2022 q3
SEC form 6
2022-11-18 16:06 ET
Iovance Biotherapeutics published news for 2022 q3
SEC form 10
2022-11-03 17:16 ET
Iovance Biotherapeutics reported for 2022 q3
SEC form 6
2022-11-03 16:05 ET
Iovance Biotherapeutics reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Iovance Biotherapeutics reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Iovance Biotherapeutics reported for 2022 q3
SEC form 6
2022-09-12 17:00 ET
Iovance Biotherapeutics published news for 2022 q2
SEC form 6
2022-08-29 17:00 ET
Iovance Biotherapeutics published news for 2022 q2
SEC form 10
2022-08-04 16:46 ET
Iovance Biotherapeutics reported for 2022 q2
SEC form 6
2022-08-04 16:05 ET
Iovance Biotherapeutics reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Iovance Biotherapeutics reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Iovance Biotherapeutics reported for 2022 q2
SEC form 6
2022-06-13 17:15 ET
Iovance Biotherapeutics published news for 2022 q1
SEC form 6
2022-05-26 17:16 ET
Iovance Biotherapeutics published news for 2022 q1
SEC form 6
2022-05-13 17:16 ET
Iovance Biotherapeutics published news for 2022 q1
SEC form 10
2022-05-05 17:16 ET
Iovance Biotherapeutics reported for 2022 q1
SEC form 6
2022-05-05 16:05 ET
Iovance Biotherapeutics reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Iovance Biotherapeutics reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Iovance Biotherapeutics reported for 2022 q1
SEC form 6
2022-04-29 17:12 ET
Iovance Biotherapeutics published news for 2022 q1
SEC form 6
2022-04-27 17:02 ET
Iovance Biotherapeutics published news for 2022 q1
SEC form 6
2022-04-05 17:00 ET
Iovance Biotherapeutics published news for 2022 q1
SEC form 10
2022-02-24 17:14 ET
Iovance Biotherapeutics published news for 2021 q4
SEC form 6
2022-02-24 16:06 ET
Iovance Biotherapeutics published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Iovance Biotherapeutics published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Iovance Biotherapeutics published news for 2021 q4
SEC form 6
2022-01-19 17:15 ET
Iovance Biotherapeutics published news for 2021 q4
SEC form 6
2022-01-10 08:16 ET
Iovance Biotherapeutics published news for 2021 q4
SEC form 10
2021-11-04 17:15 ET
Iovance Biotherapeutics published news for 2021 q3
SEC form 6
2021-11-04 16:06 ET
Iovance Biotherapeutics published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Iovance Biotherapeutics published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Iovance Biotherapeutics published news for 2021 q3
SEC form 6
2021-09-23 16:49 ET
Iovance Biotherapeutics published news for 2021 q2
SEC form 10
2021-08-05 17:18 ET
Iovance Biotherapeutics published news for 2021 q2
SEC form 6
2021-08-05 16:05 ET
Iovance Biotherapeutics published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Iovance Biotherapeutics published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Iovance Biotherapeutics published news for 2021 q2
SEC form 6
2021-06-29 16:05 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 6
2021-06-14 17:13 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 6
2021-05-20 16:06 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 6
2021-05-19 11:47 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 10
2021-05-06 17:28 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 6
2021-05-06 16:06 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 6
2021-04-27 17:20 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 6
2021-04-23 18:18 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 6
2021-04-12 16:10 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 6
2021-03-15 16:11 ET
Iovance Biotherapeutics published news for 2020 q4
SEC form 6
2021-03-12 17:15 ET
Iovance Biotherapeutics published news for 2020 q4
SEC form 6
2021-03-11 16:30 ET
Iovance Biotherapeutics published news for 2020 q4
SEC form 10
2021-02-25 17:15 ET
Iovance Biotherapeutics published news for 2020 q4
SEC form 6
2021-02-25 16:05 ET
Iovance Biotherapeutics published news for 2020 q4
SEC form 6
2021-02-09 06:01 ET
Iovance Biotherapeutics published news for 2020 q4
SEC form 6
2021-02-08 21:55 ET
Iovance Biotherapeutics published news for 2020 q4
SEC form 6
2021-01-07 06:05 ET
Iovance Biotherapeutics published news for 2020 q4
SEC form 6
2020-12-14 17:15 ET
Iovance Biotherapeutics published news for 2020 q3
SEC form 10
2020-11-05 17:16 ET
Iovance Biotherapeutics published news for 2020 q3
SEC form 6
2020-11-05 16:05 ET
Iovance Biotherapeutics published news for 2020 q3
SEC form 6
2020-10-14 17:06 ET
Iovance Biotherapeutics published news for 2020 q3
SEC form 6
2020-10-05 17:15 ET
Iovance Biotherapeutics published news for 2020 q3